Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Reaffirmed as Overweight by Cantor Fitzgerald

Posted by Brenda Bartman on Sep 28th, 2026

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a report released on Friday, Benzinga reports. They currently have a $300.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 30.29% from the stock’s previous close.

Several other equities research analysts also recently weighed in on ASND. Wall Street Zen downgraded shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings upgraded shares of Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Bank of America lowered their target price on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Royal Bank Of Canada raised their target price on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, August 14th. Finally, HC Wainwright set a $344.00 target price on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $310.75.

View Our Latest Report on ASND

Ascendis Pharma A/S Stock Up 2.1%

ASND stock traded up $4.66 during trading on Friday, hitting $230.26. 482,055 shares of the company’s stock traded hands, compared to its average volume of 696,707. The firm has a market capitalization of $14.36 billion, a P/E ratio of 17.88 and a beta of 0.35. The business has a fifty day simple moving average of $251.52 and a two-hundred day simple moving average of $242.29. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a 1 year low of $186.05 and a 1 year high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). The business had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. Sell-side analysts anticipate that Ascendis Pharma A/S will post 3.69 EPS for the current year.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, Director Jean-Jacques Bienaimé acquired 2,000 shares of the stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the purchase, the director owned 2,900 shares of the company’s stock, valued at approximately $714,357. This represents a 222.22% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the sale, the senior vice president owned 3,000 shares of the company’s stock, valued at $810,570. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 40.00% of the company’s stock.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nomura Asset Management Co. Ltd. lifted its stake in shares of Ascendis Pharma A/S by 57.5% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 43,701 shares of the biotechnology company’s stock worth $9,319,000 after buying an additional 15,950 shares during the period. Candriam S.C.A. lifted its stake in shares of Ascendis Pharma A/S by 23.2% during the first quarter. Candriam S.C.A. now owns 230,278 shares of the biotechnology company’s stock worth $52,671,000 after buying an additional 43,338 shares during the period. Orbimed Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 5.8% during the first quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company’s stock worth $41,624,000 after purchasing an additional 10,000 shares during the last quarter. Frazier Life Sciences Management L.P. raised its holdings in shares of Ascendis Pharma A/S by 68.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock worth $60,053,000 after purchasing an additional 91,822 shares during the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of Ascendis Pharma A/S by 154.6% during the first quarter. First Trust Advisors LP now owns 31,135 shares of the biotechnology company’s stock worth $7,122,000 after purchasing an additional 18,905 shares during the last quarter.

About Ascendis Pharma A/S

(Get Free Report)

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.